DE60030281T2 - Methoden zur verbesserung der sensitivität und spezifität von screeningverfahren für krebs und krebs-vorstufen - Google Patents
Methoden zur verbesserung der sensitivität und spezifität von screeningverfahren für krebs und krebs-vorstufen Download PDFInfo
- Publication number
- DE60030281T2 DE60030281T2 DE60030281T DE60030281T DE60030281T2 DE 60030281 T2 DE60030281 T2 DE 60030281T2 DE 60030281 T DE60030281 T DE 60030281T DE 60030281 T DE60030281 T DE 60030281T DE 60030281 T2 DE60030281 T2 DE 60030281T2
- Authority
- DE
- Germany
- Prior art keywords
- cancer
- sample
- nucleic acid
- primer
- precancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 105
- 201000011510 cancer Diseases 0.000 title claims abstract description 98
- 238000000034 method Methods 0.000 title claims abstract description 96
- 230000035945 sensitivity Effects 0.000 title abstract description 58
- 238000012216 screening Methods 0.000 title description 21
- 238000002360 preparation method Methods 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 84
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 84
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 84
- 238000001514 detection method Methods 0.000 claims abstract description 32
- 238000003556 assay Methods 0.000 claims abstract description 14
- 230000035772 mutation Effects 0.000 claims description 82
- 239000000523 sample Substances 0.000 claims description 64
- 208000003200 Adenoma Diseases 0.000 claims description 26
- 238000004458 analytical method Methods 0.000 claims description 22
- 206010001233 Adenoma benign Diseases 0.000 claims description 21
- 230000003321 amplification Effects 0.000 claims description 21
- 238000011835 investigation Methods 0.000 claims description 21
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 21
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 14
- 206010009944 Colon cancer Diseases 0.000 claims description 12
- 210000000349 chromosome Anatomy 0.000 claims description 12
- 239000013610 patient sample Substances 0.000 claims description 12
- 238000009396 hybridization Methods 0.000 claims description 9
- 230000000295 complement effect Effects 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 238000003753 real-time PCR Methods 0.000 claims description 5
- 210000001124 body fluid Anatomy 0.000 claims description 4
- 239000010839 body fluid Substances 0.000 claims description 4
- 210000000416 exudates and transudate Anatomy 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 206010036790 Productive cough Diseases 0.000 claims description 3
- 210000003802 sputum Anatomy 0.000 claims description 3
- 208000024794 sputum Diseases 0.000 claims description 3
- 210000002751 lymph Anatomy 0.000 claims description 2
- 210000004915 pus Anatomy 0.000 claims description 2
- 238000012163 sequencing technique Methods 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 230000002759 chromosomal effect Effects 0.000 claims 1
- 102000054765 polymorphisms of proteins Human genes 0.000 claims 1
- 201000010099 disease Diseases 0.000 description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- 238000002052 colonoscopy Methods 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 239000003550 marker Substances 0.000 description 9
- 101150105104 Kras gene Proteins 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 7
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 235000019833 protease Nutrition 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 238000007479 molecular analysis Methods 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000008707 rearrangement Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101710113436 GTPase KRas Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 208000037062 Polyps Diseases 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 210000004922 colonic epithelial cell Anatomy 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000005546 dideoxynucleotide Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000033607 mismatch repair Effects 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000000439 tumor marker Substances 0.000 description 2
- WKKCYLSCLQVWFD-UHFFFAOYSA-N 1,2-dihydropyrimidin-4-amine Chemical compound N=C1NCNC=C1 WKKCYLSCLQVWFD-UHFFFAOYSA-N 0.000 description 1
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 description 1
- 206010069755 K-ras gene mutation Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 201000002758 colorectal adenoma Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011847 diagnostic investigation Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 210000004921 distal colon Anatomy 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 238000009595 pap smear Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000002579 sigmoidoscopy Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/277,016 US6143529A (en) | 1996-08-14 | 1999-03-26 | Methods for improving sensitivity and specificity of screening assays |
| PCT/US2000/007882 WO2000058514A2 (en) | 1999-03-26 | 2000-03-24 | Methods for improving sensitivity and specificity of screening assays |
| US277016 | 2002-10-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60030281D1 DE60030281D1 (de) | 2006-10-05 |
| DE60030281T2 true DE60030281T2 (de) | 2007-08-30 |
Family
ID=23059077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60030281T Expired - Lifetime DE60030281T2 (de) | 1999-03-26 | 2000-03-24 | Methoden zur verbesserung der sensitivität und spezifität von screeningverfahren für krebs und krebs-vorstufen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6143529A (enExample) |
| EP (1) | EP1185693B1 (enExample) |
| JP (3) | JP2002539848A (enExample) |
| AT (1) | ATE337413T1 (enExample) |
| AU (1) | AU761722B2 (enExample) |
| CA (1) | CA2369045C (enExample) |
| DE (1) | DE60030281T2 (enExample) |
| WO (1) | WO2000058514A2 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6268136B1 (en) * | 1997-06-16 | 2001-07-31 | Exact Science Corporation | Methods for stool sample preparation |
| US6406857B1 (en) | 1997-06-16 | 2002-06-18 | Exact Sciences Corporation | Methods for stool sample preparation |
| US6818404B2 (en) * | 1997-10-23 | 2004-11-16 | Exact Sciences Corporation | Methods for detecting hypermethylated nucleic acid in heterogeneous biological samples |
| ATE330032T1 (de) | 1999-02-25 | 2006-07-15 | Exact Sciences Corp | Verfahren zur erhaltung der dns-integrität |
| CA2366778C (en) * | 1999-04-09 | 2008-07-22 | Exact Sciences Corporation | Methods for detecting nucleic acids indicative of cancer |
| US6586177B1 (en) * | 1999-09-08 | 2003-07-01 | Exact Sciences Corporation | Methods for disease detection |
| US6849403B1 (en) * | 1999-09-08 | 2005-02-01 | Exact Sciences Corporation | Apparatus and method for drug screening |
| EP1238113B1 (en) | 1999-12-07 | 2010-02-24 | EXACT Sciences Corporation | Detection of lung neoplasms in stool |
| US6919174B1 (en) * | 1999-12-07 | 2005-07-19 | Exact Sciences Corporation | Methods for disease detection |
| US7250252B2 (en) * | 1999-12-30 | 2007-07-31 | David Aaron Katz | Amplification based polymorphism detection |
| US6585646B2 (en) * | 2000-11-29 | 2003-07-01 | Hermetic Diagnostics, Inc. | Screening test and procedure using skin patches |
| US6911308B2 (en) * | 2001-01-05 | 2005-06-28 | Exact Sciences Corporation | Methods for detecting, grading or monitoring an H. pylori infection |
| US6428964B1 (en) | 2001-03-15 | 2002-08-06 | Exact Sciences Corporation | Method for alteration detection |
| US6727354B2 (en) * | 2001-12-12 | 2004-04-27 | Quest Diagnostics Investments, Inc. | Compositions and methods for TIGR genotyping assays |
| US20030180765A1 (en) * | 2002-02-01 | 2003-09-25 | The Johns Hopkins University | Digital amplification for detection of mismatch repair deficient tumor cells |
| WO2003071252A2 (en) | 2002-02-15 | 2003-08-28 | Exact Sciences Corporation | Methods for analysis of molecular events |
| CA2506066A1 (en) * | 2002-11-15 | 2004-06-03 | Genomic Health, Inc. | Gene expression profiling of egfr positive cancer |
| US20040231909A1 (en) | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
| WO2004071572A2 (en) * | 2003-02-06 | 2004-08-26 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
| CA2516553C (en) * | 2003-02-20 | 2013-04-16 | Genomic Health, Inc. | Use of intronic rna to measure gene expression |
| ITMI20030434A1 (it) | 2003-03-07 | 2004-09-08 | Istituto Oncologico Romagnolo Coope Rativa Sociale | Metodo per l'individuazione di tumori del colon-retto. |
| CA2527321A1 (en) * | 2003-05-30 | 2004-12-23 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
| WO2005039382A2 (en) * | 2003-06-24 | 2005-05-06 | Genomic Health | Prediction of likelihood of cancer recurrence |
| EP1644858B1 (en) | 2003-07-10 | 2017-12-06 | Genomic Health, Inc. | Expression profile algorithm and test for cancer prognosis |
| AU2004284434A1 (en) * | 2003-10-16 | 2005-05-06 | Genomic Health, Inc. | qRT-PCR assay system for gene expression profiling |
| JP4718490B2 (ja) * | 2003-12-23 | 2011-07-06 | ジェノミック ヘルス， インコーポレイテッド | フラグメント化ｒｎａの全般的増幅 |
| CA2848463A1 (en) | 2004-04-09 | 2005-10-27 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| EP1751306A1 (en) * | 2004-04-30 | 2007-02-14 | Yale University | Methods and compositions for cancer diagnosis |
| WO2006026654A2 (en) | 2004-08-27 | 2006-03-09 | Exact Sciences Corporation | Method for detecting a recombinant event |
| WO2006047481A2 (en) * | 2004-10-22 | 2006-05-04 | Redpath Integrated Pathology, Inc. | Enhanced amplifiability of minute fixative-treated tissue samples, minute stained cytology samples, and other minute sources of dna |
| US9109256B2 (en) | 2004-10-27 | 2015-08-18 | Esoterix Genetic Laboratories, Llc | Method for monitoring disease progression or recurrence |
| JP4939425B2 (ja) * | 2004-11-05 | 2012-05-23 | ジェノミック ヘルス， インコーポレイテッド | 乳癌の治療反応の予後および予測の分子指標 |
| CA3061785A1 (en) | 2004-11-05 | 2006-05-18 | Genomic Health, Inc. | Predicting response to chemotherapy using gene expression markers |
| WO2006094149A2 (en) * | 2005-03-01 | 2006-09-08 | Exact Sciences Corporation | Methods and compositions for detecting adenoma |
| US9777314B2 (en) | 2005-04-21 | 2017-10-03 | Esoterix Genetic Laboratories, Llc | Analysis of heterogeneous nucleic acid samples |
| US20070248546A1 (en) * | 2005-11-09 | 2007-10-25 | Exact Sciences Corporation | Clinical algorithm for excluding patients identified in virtual imaging |
| JPWO2008090930A1 (ja) * | 2007-01-23 | 2010-05-20 | オリンパス株式会社 | 癌の診断方法 |
| EP2218792A4 (en) * | 2007-11-20 | 2010-12-08 | Olympus Corp | PROCESS FOR PREPARATION OF A KOTPROBE, SOLUTION FOR PREPARATION OF A KOTPROBE AND KOTSAMMELKIT |
| WO2009102788A2 (en) | 2008-02-15 | 2009-08-20 | Mayo Foundation For Medical Education And Research | Detecting neoplasm |
| GB201107466D0 (en) | 2011-05-05 | 2011-06-15 | Loktionov Alexandre | Device and method for non-invasive collection of colorectal mucocellular layer and disease detection |
| US9341628B2 (en) | 2012-11-30 | 2016-05-17 | Interpace Diagnostics Corporation | Methods for measuring carcinoembryonic antigen |
| JP6294614B2 (ja) | 2013-05-08 | 2018-03-14 | 有限会社マイテック | 癌関連物質の定量方法 |
| US10253358B2 (en) | 2013-11-04 | 2019-04-09 | Exact Sciences Development Company, Llc | Multiple-control calibrators for DNA quantitation |
| EP3084004A4 (en) | 2013-12-19 | 2017-08-16 | Exact Sciences Corporation | Synthetic nucleic acid control molecules |
| US10184154B2 (en) | 2014-09-26 | 2019-01-22 | Mayo Foundation For Medical Education And Research | Detecting cholangiocarcinoma |
| CN107532124B (zh) | 2015-03-27 | 2022-08-09 | 精密科学公司 | 检测食管疾病 |
| ES2902174T3 (es) | 2016-07-19 | 2022-03-25 | Exact Sciences Dev Co Llc | ADN de control metilado |
| EP3488003B1 (en) | 2016-07-19 | 2023-10-25 | Exact Sciences Corporation | Nucleic acid control molecules from non-human organisms |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE501439C2 (sv) * | 1993-06-22 | 1995-02-13 | Pharmacia Lkb Biotech | Sätt och anordning för analys av polynukleotidsekvenser |
| AU5310296A (en) * | 1995-03-17 | 1996-10-08 | John Wayne Cancer Institute | Detection of melanoma or breast metastases with a multiple marker assay |
| DE19736691A1 (de) * | 1997-08-22 | 1999-02-25 | Michael Prof Dr Med Giesing | Verfahren zur Charakterisierung und Identifizierung disseminierter und metastasierter Krebszellen |
-
1999
- 1999-03-26 US US09/277,016 patent/US6143529A/en not_active Expired - Lifetime
-
2000
- 2000-03-24 WO PCT/US2000/007882 patent/WO2000058514A2/en not_active Ceased
- 2000-03-24 AT AT00918364T patent/ATE337413T1/de not_active IP Right Cessation
- 2000-03-24 DE DE60030281T patent/DE60030281T2/de not_active Expired - Lifetime
- 2000-03-24 AU AU39189/00A patent/AU761722B2/en not_active Ceased
- 2000-03-24 JP JP2000608792A patent/JP2002539848A/ja active Pending
- 2000-03-24 CA CA2369045A patent/CA2369045C/en not_active Expired - Fee Related
- 2000-03-24 EP EP00918364A patent/EP1185693B1/en not_active Expired - Lifetime
-
2010
- 2010-05-17 JP JP2010113710A patent/JP2010172347A/ja active Pending
-
2013
- 2013-03-21 JP JP2013057677A patent/JP2013116131A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1185693A2 (en) | 2002-03-13 |
| WO2000058514A3 (en) | 2001-12-13 |
| CA2369045C (en) | 2010-06-01 |
| JP2010172347A (ja) | 2010-08-12 |
| EP1185693B1 (en) | 2006-08-23 |
| DE60030281D1 (de) | 2006-10-05 |
| AU3918900A (en) | 2000-10-16 |
| JP2002539848A (ja) | 2002-11-26 |
| CA2369045A1 (en) | 2000-10-05 |
| AU761722B2 (en) | 2003-06-05 |
| ATE337413T1 (de) | 2006-09-15 |
| US6143529A (en) | 2000-11-07 |
| WO2000058514A2 (en) | 2000-10-05 |
| JP2013116131A (ja) | 2013-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60030281T2 (de) | Methoden zur verbesserung der sensitivität und spezifität von screeningverfahren für krebs und krebs-vorstufen | |
| DE69629363T2 (de) | Verfahren zum nachweis von kolonkrebs aus stuhlproben | |
| DE60029092T2 (de) | Verfahren zur detektion von nukleinsäuren, welche auf krebs hinweisen | |
| DE68927059T2 (de) | In-situ-unterdrückungs-hybridisierung und verwendungen | |
| DE68928500T2 (de) | Nachweis des menschlichen tumorfortschrittes und heilmittelwiderstandes | |
| DE69632252T2 (de) | Verfahren zur erkennung von klonalen populationen von transformierten zellen in einer genomisch heterogenen zellulären probe | |
| DE69630234T2 (de) | Verfahren zur bestimung von ki-ras mutationen und dieses leistender testsatz | |
| EP0438512B2 (de) | Verfahren zur analyse von längenpolymorphismen in dna-bereichen | |
| JP2003508083A (ja) | 疾患検出のための方法 | |
| WO2001042502A2 (en) | Methods for disease detection | |
| AU767833B2 (en) | Methods of detecting colorectal disease | |
| DE602004004988T2 (de) | Methylierungsstatus-Detektionsassays mittels methylierungsspezifischer Primerextension (MSPE) | |
| DE69704031T2 (de) | Test zur diagnose eines erhöhten brustkrebs-risikos | |
| DE112008001164T5 (de) | Gensignatur der frühen Hypoxie zur Vorhersage des Patientenüberlebens | |
| EP2935621B1 (de) | Verfahren zur bestiummung des dna-methylierungsgrads | |
| US20040259101A1 (en) | Methods for disease screening | |
| DE60025871T2 (de) | Genetisches Screening Verfahren und Vorrichtung | |
| DE102017214449B4 (de) | Verfahren und Mittel zur Diagnostik von Tumoren durch Nachweis und Quantifizierung heterogen methylierter Epiallele | |
| DE69828647T2 (de) | Diagnostisches assay zur krebsanfälligkeit | |
| DE60316464T2 (de) | Neue real-time rt-pcr methode zur sensitiven detektierung mehrerer mage gen transkripte | |
| DE10353419B3 (de) | Verfahren zur Untersuchung von Cytosin-Methylierungen in DNA-Sequenzen mittels hemimethylierungssensitiver Restriktionsenzyme | |
| DE102005011003B4 (de) | Verfahren und Mittel zur differentiellen Diagnose von Schilddrüsentumoren | |
| JP2024034434A (ja) | 高感度かつ定量的な遺伝子検査方法 | |
| DE10030827A1 (de) | Verfahren zum Nachweis von Cathepsinen, Asparaginylendopeptidase und deren Isozyme, sowie von Leukocystatin | |
| EP3004384A2 (de) | Verfahren zum auffinden von nucleinsäuren, nucleinsäuren sowie dazu komplementäre oligonucleotide zur identifikation von biologischem material, sowie verfahren zur identifikation von biologischem material und kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: GENZYME CORP., CAMBRIDGE, MASS., US |
|
| R082 | Change of representative |
Ref document number: 1185693 Country of ref document: EP Representative=s name: KLUNKER, SCHMITT-NILSON, HIRSCH, 80796 MUENCHEN, D |